Doctors at Evelina Children's Hospital in London have invented one of Europe's top-selling medical iPhone applications, with more than 100 downloads every week. The Paediatric Emergency Drugs app enables medical and nursing staff to quickly work out complicated drug calculations during emergencies to ensure paediatric patients receive the correct drug doses for their age and weight. Paediatric intensive care consultant, Dr Shelley Riphagen, came up with the idea with the help of Dr Andrew Durward's IT skills and the app went on sale in March this year. Dr Riphagen said: "When critically-ill children present to district general hospitals with emergencies, the right doses of drugs according to the child's age and weight need to be available immediately. The Paediatric Emergency Drugs app allows this to happen. It has made a huge difference to the care of our patients and it's really fantastic to know that it's also appreciated by medical and nursing staff in hospitals across Europe." The project was made possible through collaboration with UBQO.
Medical app is best seller
You may also like
Trending Articles
You may also like
Digital
Abolis launches microbial intelligence platform to optimise bioprocess development
The company has launched MINE, a multi-omics platform designed to help pharmaceutical and other industrial R&D teams identify microbial production pathways, prioritise experiments and support fermentation process optimisation and scale-up
Digital
Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow
The autoloMATE-powered platform connects sample submission, laboratory execution and review into a single digital workflow across Charles River's North American and European Biologics Testing Solutions sites — replacing paper-based processes to accelerate client results
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October